지질 나노입자 제조 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2031년)

Lipid Nanoparticle Manufacturing Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

US $ 4,995 ￦ 7,030,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,267,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,956,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

Persistence Market Research는 최근 지질 나노입자 제조 세계 시장에 대한 종합적인 보고서를 발표했습니다. 이 보고서는 시장 촉진요인, 동향, 기회, 촉진요인, 과제 등 중요한 시장 역학을 철저히 평가하고 시장 구조에 대한 심층적인 인사이트를 제공합니다. 이 보고서는 2024년부터 2031년까지 세계 지질 나노입자 제조 시장의 예측 성장 궤적을 개괄하는 독점 데이터와 통계를 제공합니다.

주요 인사이트

• 지질 나노입자 제조 시장 규모(2024년) : 8억 9,330만 달러
• 예상 시장 가치(2031년) : 18억 달러
• 세계 시장 성장률(2024-2031년 CAGR) : 10.4%

지질 나노입자 제조 시장 - 보고서 범위:

지질 나노입자는 치료제, 백신, 유전자 표적 전달을 위해 제약 및 생명공학 분야에서 널리 사용되는 다목적 약물전달 시스템입니다. 이 시장은 mRNA 백신, 암 치료 및 기타 첨단 약물 제제를 포함한 다양한 응용 분야에 적용되고 있습니다. 지질 나노입자 제조의 성장은 활발한 R&D 활동, 효율적인 약물전달 시스템에 대한 수요 증가, 지질 제제 기술의 발전으로 인해 치료제의 생체 이용률과 안정성이 향상됨에 따라 성장하고 있습니다.

시장 촉진요인:

세계 지질 나노입자 제조 시장은 몇 가지 중요한 요인에 의해 주도되고 있으며, 특히 COVID-19 팬데믹으로 인한 mRNA 백신에 대한 수요가 급증하면서 백신 전달에 있어 지질 나노입자의 효능이 부각되고 있습니다. 또한, 만성 질환의 유병률 증가와 새로운 치료 접근법의 필요성이 지질 나노입자 기술에 대한 투자 증가를 촉진하고 있습니다. 지질 나노입자를 이용한 표적 약물전달 시스템의 개발은 치료 효과 향상, 부작용 감소, 환자 순응도 향상을 통해 시장 확대를 더욱 촉진할 수 있습니다.

시장 억제요인:

유망한 성장 전망에도 불구하고 지질 나노입자 제조 시장은 규제 장벽, 높은 제조 비용 및 확장성 문제와 관련된 도전에 직면해 있습니다. 지질 기반 제제에 대한 엄격한 규제 요건은 승인 일정이 길어지고 신제품의 시장 진입에 영향을 미칠 수 있습니다. 또한, 복잡한 제조 공정과 특수 장비가 필요하기 때문에 제조 비용이 높아져 특히 중소기업의 시장 진입에 어려움을 겪고 있습니다. 이러한 규제 및 경제적 장벽을 극복하기 위해서는 업계 이해관계자와 규제 당국이 협력하여 승인 절차를 간소화하고 제품 안전성을 보장해야 합니다.

시장 기회:

지질 나노입자 제조 시장은 기술 혁신과 다양한 치료 분야로의 응용 확대에 따라 큰 성장 기회를 제공하고 있습니다. 개인 맞춤형 의료에 대한 관심이 높아지면서 맞춤형 지질 제제의 시장 개척이 진행됨에 따라 시장 관계자들에게 새로운 길을 열어줄 것으로 기대됩니다. 또한, 치료 효과를 높이기 위해 지질 나노입자를 이용한 병용요법이 증가하고 있는 추세도 시장의 영역을 넓히고 있습니다. 연구개발에 대한 전략적 투자, 제약사와의 제휴, 나노기술의 발전은 새로운 기회를 활용하고 시장 리더십을 유지하는 데 필수적입니다.

본 보고서에서 다루는 주요 질문들

• 세계 지질 나노입자 제조 시장의 성장을 촉진하는 주요 요인은 무엇인가?
• 다양한 의료 환경에서 지질 나노입자의 채택을 촉진하는 응용 및 치료 분야는 무엇인가?
• 기술의 발전은 지질 나노입자 생산의 경쟁 구도를 어떻게 변화시키고 있는가?
• 지질 나노입자 제조 시장에 기여하는 주요 기업은 어디에 있으며, 시장 관련성을 유지하기 위해 어떤 전략을 채택하고 있는가?
• 세계 지질 나노입자 제조 시장의 새로운 동향과 향후 전망은?

목차

제1장 주요 요약

제2장 시장 개요

• 시장 범위와 정의
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 주요 동향
• 거시경제 요인
  • 세계의 부문별 전망
  • 세계의 GDP 성장 전망
  • 세계의 헬스케어비 지출 전망
• COVID-19의 영향 분석
• 예측요인 - 관련성과 영향

제3장 부가가치 인사이트

• 제품 채용 분석
• 기술 평가
• 규제 상황
• 공급망 분석
• 주요 거래와 합병
• PESTLE 분석
• Porter's Five Forces 분석

제4장 세계의 지질 나노입자 제조 시장 전망 : 실적(2019-2023년) 및 예측(2024-2031년)

• 주요 하이라이트
  • 시장 규모와 전년비 성장률
  • 절대적액 기회
• 시장 규모 분석과 예측
  • 과거 시장 규모 분석 : 2019-2023년
  • 현재 시장 규모 분석과 예측 : 2024-2031년
• 세계의 지질 나노입자 제조 시장 전망 : LNP 유형별
  • 소개/주요 조사 결과
  • 과거 시장 규모 분석 : LNP 유형별, 2019-2023년
  • 현재 시장 규모 분석과 예측 : LNP 유형별, 2024-2031년
    • 고체 지질 나노입자(SLN)
    • 나노구조 지질 캐리어(NLC)
• 시장 매력 분석 : LNP 유형별
• 세계의 지질 나노입자 제조 시장 전망 : 치료 분야별
  • 소개/주요 조사 결과
  • 과거 시장 규모 분석 : 치료 분야별, 2019-2023년
  • 현재 시장 규모 분석과 예측 : 치료 분야별, 2024-2031년
    • 감염증
    • 희귀질환
    • 종양성 질환
    • 신경변성질환
    • 기타
• 시장 매력 분석 : 치료 분야별
• 세계의 지질 나노입자 제조 시장 전망 : 최종사용자별
  • 소개/주요 조사 결과
  • 과거 시장 규모 분석 : 최종사용자별, 2019-2023년
  • 현재 시장 규모 분석과 예측 : 최종사용자별, 2024-2031년
    • 제약·바이오테크놀러지 기업
    • 학술조사기관
    • 기타
• 시장 매력 분석 : 최종사용자별

제5장 세계의 지질 나노입자 제조 시장 전망 : 지역별

• 주요 하이라이트
• 과거 시장 규모 분석 : 지역별, 2019-2023년
• 현재 시장 규모 분석과 예측 : 지역별, 2024-2031년
  • 북미
  • 유럽
  • 동아시아
  • 남아시아와 오세아니아
  • 라틴아메리카
  • 중동 및 아프리카
• 시장 매력 분석 : 지역별

제6장 북미의 지질 나노입자 제조 시장 전망 : 실적(2019-2023년) 및 예측(2024-2031년)

제7장 유럽의 지질 나노입자 제조 시장 전망 : 실적(2019-2023년) 및 예측(2024-2031년)

제8장 동아시아의 지질 나노입자 제조 시장 전망 : 실적(2019-2023년) 및 예측(2024-2031년)

제9장 남아시아 및 오세아니아의 지질 나노입자 제조 시장 전망 : 실적(2019-2023년) 및 예측(2024-2031년)

제10장 라틴아메리카의 지질 나노입자 제조 시장 전망 : 실적(2019-2023년) 및 예측(2024-2031년)

제11장 중동 및 아프리카의 지질 나노입자 제조 시장 전망 : 실적(2019-2023년) 및 예측(2024-2031년)

제12장 경쟁 상황

• 시장 점유율 분석, 2024년
• 시장 구조
  • 시장별 경쟁 격화 맵
  • 경쟁 대시보드
• 기업 개요(상세 - 개요, 재무, 전략, 최근의 동향)
  • Certest Biotec
  • Evonik
  • Ascendia Pharmaceuticals
  • Lonza
  • Exelead(Merck KGaA)
  • CordenPharma
  • Curia Global, Inc.
  • Creative Biostructure
  • CD Bioparticles
  • BOC Sciences
  • Acuitas Therapeutics
  • ABP Biosciences, LLC
  • Recipharm AB

제13장 부록

• 조사 방법
• 조사 가정
• 두문자어와 약어

ksm

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the worldwide market for lipid nanoparticle manufacturing. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global lipid nanoparticle manufacturing market from 2024 to 2031.

Key Insights:

• Lipid Nanoparticle Manufacturing Market Size (2024E):US$893.3 Mn
• Projected Market Value (2031F): US$1.8 Bn
• Global Market Growth Rate (CAGR 2024 to 2031):10.4%

Lipid Nanoparticle Manufacturing Market - Report Scope:

Lipid nanoparticles are versatile drug delivery systems used extensively in pharmaceuticals and biotechnology for the targeted delivery of therapeutics, vaccines, and genes. This market caters to various applications, including mRNA vaccines, cancer therapies, and other advanced drug formulations. The growth of lipid nanoparticle manufacturing is driven by increased research and development activities, heightened demand for efficient drug delivery systems, and advancements in lipid formulation technologies, thereby enhancing the bioavailability and stability of therapeutic agents.

Market Growth Drivers:

The global lipid nanoparticle manufacturing market is propelled by several key factors, including the surge in demand for mRNA vaccines, particularly in the wake of the COVID-19 pandemic, which has underscored the efficacy of lipid nanoparticles in vaccine delivery. Additionally, the growing prevalence of chronic diseases and the need for novel therapeutic approaches foster increased investment in lipid nanoparticle technologies. The development of targeted drug delivery systems utilizing lipid nanoparticles enables improved treatment efficacy, reduced side effects, and enhanced patient compliance, further driving market expansion.

Market Restraints:

Despite promising growth prospects, the lipid nanoparticle manufacturing market faces challenges related to regulatory hurdles, high production costs, and scalability issues. Stringent regulatory requirements for lipid-based formulations can lead to prolonged approval timelines, affecting market entry for new products. Moreover, the complex manufacturing processes and the necessity for specialized equipment contribute to high production costs, posing challenges for market penetration, especially for small and medium enterprises. Addressing these regulatory and economic barriers requires collaboration between industry stakeholders and regulatory bodies to streamline approval processes and ensure product safety.

Market Opportunities:

The lipid nanoparticle manufacturing market presents significant growth opportunities driven by technological innovations and expanding applications across various therapeutic areas. The increasing focus on personalized medicine and the development of tailored lipid formulations are expected to create new avenues for market players. Moreover, the rising trend of combination therapies utilizing lipid nanoparticles for enhanced therapeutic outcomes broadens the market scope. Strategic investments in research and development, partnerships with pharmaceutical companies, and advancements in nanotechnology are essential to capitalize on emerging opportunities and sustain market leadership.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the lipid nanoparticle manufacturing market globally?
• Which applications and therapeutic areas are driving the adoption of lipid nanoparticles across different healthcare settings?
• How are technological advancements reshaping the competitive landscape of lipid nanoparticle manufacturing?
• Who are the key players contributing to the lipid nanoparticle manufacturing market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global lipid nanoparticle manufacturing market?

Competitive Intelligence and Business Strategy:

Leading players in the global lipid nanoparticle manufacturing market, including Moderna, Inc., BioNTech SE, and C3S, focus on innovation, product differentiation, and strategic collaborations to gain a competitive edge. These companies invest significantly in R&D to develop advanced lipid formulations and manufacturing techniques that cater to diverse therapeutic needs. Collaborations with research institutions, pharmaceutical companies, and regulatory agencies facilitate market access and promote technology adoption. Furthermore, an emphasis on clinical trials, evidence-based research, and patient education enhances market growth and improves therapeutic outcomes in the rapidly evolving lipid nanoparticle landscape.

Key Companies Profiled:

• Moderna, Inc.
• BioNTech SE
• C3S
• Pfizer Inc.
• Dicerna Pharmaceuticals, Inc.
• Novavax, Inc.
• Translate Bio, Inc.
• Arcturus Therapeutics
• Lipid Therapeutics GmbH
• Dendritic NanoTechnologies

Lipid Nanoparticle Manufacturing Market Segmentation

By Type of LNP

• Solid Lipid Nanoparticles (SLNs)
• Nanostructured Lipid Carriers (NLCs)

By Therapeutic Area

• Infectious Diseases
• Rare Diseases
• Oncological Disorders
• Neurodegenerative Disorders

By End User

• Pharmaceutical and Biotechnology Companies
• Academic & Research Institutes

By Region

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Lipid Nanoparticle Manufacturing Market Snapshot, 2024-2031
• 1.2. Market Opportunity Assessment, 2024-2031, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
  • 2.3.3. Global Healthcare Spending Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Product Adoption Analysis
• 3.2. Technology Assessment
• 3.3. Regulatory Landscape
• 3.4. Supply Chain Analysis
• 3.5. Key Deals and Mergers
• 3.6. PESTLE Analysis
• 3.7. Porter's Five Force Analysis

4. Global Lipid Nanoparticle Manufacturing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Mn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2023
  • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2024-2031
• 4.3. Global Lipid Nanoparticle Manufacturing Market Outlook: Type of LNP
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Type of LNP, 2019-2023
  • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Type of LNP, 2024-2031
    • 4.3.3.1. Solid Lipid Nanoparticles (SLNs)
    • 4.3.3.2. Nanostructured Lipid Carriers (NLCs)
• 4.4. Market Attractiveness Analysis: Type of LNP
• 4.5. Global Lipid Nanoparticle Manufacturing Market Outlook: Therapeutic Area
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Mn) Analysis, By Therapeutic Area, 2019-2023
  • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
    • 4.5.3.1. Infectious Diseases
    • 4.5.3.2. Rare Diseases
    • 4.5.3.3. Oncological Disorders
    • 4.5.3.4. Neurodegenerative Disorders
    • 4.5.3.5. Others
• 4.6. Market Attractiveness Analysis: Therapeutic Area
• 4.7. Global Lipid Nanoparticle Manufacturing Market Outlook: End User
  • 4.7.1. Introduction / Key Findings
  • 4.7.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2023
  • 4.7.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
    • 4.7.3.1. Pharmaceutical and Biotechnology Companies
    • 4.7.3.2. Academic & Research Institutes
    • 4.7.3.3. Others
• 4.8. Market Attractiveness Analysis: End User

5. Global Lipid Nanoparticle Manufacturing Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2023
• 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2024-2031
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Lipid Nanoparticle Manufacturing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 6.2.1. By Country
  • 6.2.2. By Type of LNP
  • 6.2.3. By Therapeutic Area
  • 6.2.4. By End User
• 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of LNP, 2024-2031
  • 6.4.1. Solid Lipid Nanoparticles (SLNs)
  • 6.4.2. Nanostructured Lipid Carriers (NLCs)
• 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
  • 6.5.1. Infectious Diseases
  • 6.5.2. Rare Diseases
  • 6.5.3. Oncological Disorders
  • 6.5.4. Neurodegenerative Disorders
  • 6.5.5. Others
• 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 6.6.1. Pharmaceutical and Biotechnology Companies
  • 6.6.2. Academic & Research Institutes
  • 6.6.3. Others
• 6.7. Market Attractiveness Analysis

7. Europe Lipid Nanoparticle Manufacturing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 7.2.1. By Country
  • 7.2.2. By Type of LNP
  • 7.2.3. By Therapeutic Area
  • 7.2.4. By End User
• 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkiye
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of LNP, 2024-2031
  • 7.4.1. Solid Lipid Nanoparticles (SLNs)
  • 7.4.2. Nanostructured Lipid Carriers (NLCs)
• 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
  • 7.5.1. Infectious Diseases
  • 7.5.2. Rare Diseases
  • 7.5.3. Oncological Disorders
  • 7.5.4. Neurodegenerative Disorders
  • 7.5.5. Others
• 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 7.6.1. Pharmaceutical and Biotechnology Companies
  • 7.6.2. Academic & Research Institutes
  • 7.6.3. Others
• 7.7. Market Attractiveness Analysis

8. East Asia Lipid Nanoparticle Manufacturing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 8.2.1. By Country
  • 8.2.2. By Type of LNP
  • 8.2.3. By Therapeutic Area
  • 8.2.4. By End User
• 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of LNP, 2024-2031
  • 8.4.1. Solid Lipid Nanoparticles (SLNs)
  • 8.4.2. Nanostructured Lipid Carriers (NLCs)
• 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
  • 8.5.1. Infectious Diseases
  • 8.5.2. Rare Diseases
  • 8.5.3. Oncological Disorders
  • 8.5.4. Neurodegenerative Disorders
  • 8.5.5. Others
• 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 8.6.1. Pharmaceutical and Biotechnology Companies
  • 8.6.2. Academic & Research Institutes
  • 8.6.3. Others
• 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Lipid Nanoparticle Manufacturing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 9.2.1. By Country
  • 9.2.2. By Type of LNP
  • 9.2.3. By Therapeutic Area
  • 9.2.4. By End User
• 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of LNP, 2024-2031
  • 9.4.1. Solid Lipid Nanoparticles (SLNs)
  • 9.4.2. Nanostructured Lipid Carriers (NLCs)
• 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
  • 9.5.1. Infectious Diseases
  • 9.5.2. Rare Diseases
  • 9.5.3. Oncological Disorders
  • 9.5.4. Neurodegenerative Disorders
  • 9.5.5. Others
• 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 9.6.1. Pharmaceutical and Biotechnology Companies
  • 9.6.2. Academic & Research Institutes
  • 9.6.3. Others
• 9.7. Market Attractiveness Analysis

10. Latin America Lipid Nanoparticle Manufacturing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 10.2.1. By Country
  • 10.2.2. By Type of LNP
  • 10.2.3. By Therapeutic Area
  • 10.2.4. By End User
• 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of LNP, 2024-2031
  • 10.4.1. Solid Lipid Nanoparticles (SLNs)
  • 10.4.2. Nanostructured Lipid Carriers (NLCs)
• 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
  • 10.5.1. Infectious Diseases
  • 10.5.2. Rare Diseases
  • 10.5.3. Oncological Disorders
  • 10.5.4. Neurodegenerative Disorders
  • 10.5.5. Others
• 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 10.6.1. Pharmaceutical and Biotechnology Companies
  • 10.6.2. Academic & Research Institutes
  • 10.6.3. Others
• 10.7. Market Attractiveness Analysis

11. Middle East & Africa Lipid Nanoparticle Manufacturing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 11.2.1. By Country
  • 11.2.2. By Type of LNP
  • 11.2.3. By Therapeutic Area
  • 11.2.4. By End User
• 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of LNP, 2024-2031
  • 11.4.1. Solid Lipid Nanoparticles (SLNs)
  • 11.4.2. Nanostructured Lipid Carriers (NLCs)
• 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2024-2031
  • 11.5.1. Infectious Diseases
  • 11.5.2. Rare Diseases
  • 11.5.3. Oncological Disorders
  • 11.5.4. Neurodegenerative Disorders
  • 11.5.5. Others
• 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
  • 11.6.1. Pharmaceutical and Biotechnology Companies
  • 11.6.2. Academic & Research Institutes
  • 11.6.3. Others
• 11.7. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2024
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Certest Biotec
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Evonik
    • 12.3.2.1. Overview
    • 12.3.2.2. Segments and Products
    • 12.3.2.3. Key Financials
    • 12.3.2.4. Market Developments
    • 12.3.2.5. Market Strategy
  • 12.3.3. Ascendia Pharmaceuticals
    • 12.3.3.1. Overview
    • 12.3.3.2. Segments and Products
    • 12.3.3.3. Key Financials
    • 12.3.3.4. Market Developments
    • 12.3.3.5. Market Strategy
  • 12.3.4. Lonza
    • 12.3.4.1. Overview
    • 12.3.4.2. Segments and Products
    • 12.3.4.3. Key Financials
    • 12.3.4.4. Market Developments
    • 12.3.4.5. Market Strategy
  • 12.3.5. Exelead (Merck KGaA)
    • 12.3.5.1. Overview
    • 12.3.5.2. Segments and Products
    • 12.3.5.3. Key Financials
    • 12.3.5.4. Market Developments
    • 12.3.5.5. Market Strategy
  • 12.3.6. CordenPharma
    • 12.3.6.1. Overview
    • 12.3.6.2. Segments and Products
    • 12.3.6.3. Key Financials
    • 12.3.6.4. Market Developments
    • 12.3.6.5. Market Strategy
  • 12.3.7. Curia Global, Inc.
    • 12.3.7.1. Overview
    • 12.3.7.2. Segments and Products
    • 12.3.7.3. Key Financials
    • 12.3.7.4. Market Developments
    • 12.3.7.5. Market Strategy
  • 12.3.8. Creative Biostructure
    • 12.3.8.1. Overview
    • 12.3.8.2. Segments and Products
    • 12.3.8.3. Key Financials
    • 12.3.8.4. Market Developments
    • 12.3.8.5. Market Strategy
  • 12.3.9. CD Bioparticles
    • 12.3.9.1. Overview
    • 12.3.9.2. Segments and Products
    • 12.3.9.3. Key Financials
    • 12.3.9.4. Market Developments
    • 12.3.9.5. Market Strategy
  • 12.3.10. BOC Sciences
    • 12.3.10.1. Overview
    • 12.3.10.2. Segments and Products
    • 12.3.10.3. Key Financials
    • 12.3.10.4. Market Developments
    • 12.3.10.5. Market Strategy
  • 12.3.11. Acuitas Therapeutics
    • 12.3.11.1. Overview
    • 12.3.11.2. Segments and Products
    • 12.3.11.3. Key Financials
    • 12.3.11.4. Market Developments
    • 12.3.11.5. Market Strategy
  • 12.3.12. ABP Biosciences, LLC
    • 12.3.12.1. Overview
    • 12.3.12.2. Segments and Products
    • 12.3.12.3. Key Financials
    • 12.3.12.4. Market Developments
    • 12.3.12.5. Market Strategy
  • 12.3.13. Recipharm AB
    • 12.3.13.1. Overview
    • 12.3.13.2. Segments and Products
    • 12.3.13.3. Key Financials
    • 12.3.13.4. Market Developments
    • 12.3.13.5. Market Strategy

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations

관련자료